Uli Stilz

Bio:

Uli Stilz builds and scales therapeutics companies and platforms at the intersection of
emerging biology, new modalities, and AI—translating scientific breakthroughs into durable
therapeutic impact.    
As Senior Advisor at Flagship Pioneering, he works on company creation, platform
development, and scaling platform companies through their growth phase, integrating
science, capital, and execution.    
Previously, Uli was Corporate Vice President at Novo Nordisk, where he led External
Innovation globally. He founded and scaled the Bio Innovation Hub, establishing a venturestyle R&D platform that built a multi-asset portfolio with a strong emphasis on first-in-class
programs and novel modalities, contributing significantly to Novo Nordisk’s early-stage
pipeline.    
Over a 30-year career spanning Sanofi and Novo Nordisk, Uli has contributed to more than
60 drug candidates, including 30 INDs, across cardiometabolic, immunology, and oncology.    
Uli serves on the Board of Aerska Therapeutics and is Chair of the Scientific Advisory Board
at CaVos. He is Vice Chair of the Kendall Square Association and a Strategic Advisor to
Jefferson Life Sciences and other investment organizations.    
Uli trained in organic chemistry at ETH Zürich and completed his PhD at the Max Planck
Institute of Biochemistry under Nobel laureate Hartmut Michel and Professor Dieter
Oesterhelt, followed by postdoctoral research at Caltech with Peter Dervan.    
He previously served as President of the European Federation for Medicinal Chemistry
(EFMC) and was recognized as an EFMC Honoree (2020) and Fierce 50 Innovation Honoree
(2024).